OTCMKTS:RDGL Vivos (RDGL) Stock Price, News & Analysis $0.14 +0.00 (+0.58%) As of 05/1/2025 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock About Vivos Stock (OTCMKTS:RDGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos alerts:Sign Up Key Stats Today's Range$0.13▼$0.1550-Day Range$0.10▼$0.1452-Week Range$0.06▼$0.26Volume917,159 shsAverage Volume1.01 million shsMarket Capitalization$63.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.Read More… Vivos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreRDGL MarketRank™: Vivos scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Vivos. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos is -13.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vivos' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.06% of the float of Vivos has been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently increased by 270.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos does not currently pay a dividend.Dividend GrowthVivos does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.06% of the float of Vivos has been sold short.Short Interest Ratio / Days to CoverVivos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos has recently increased by 270.00%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.48 News SentimentVivos has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vivos this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for RDGL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos insiders have not sold or bought any company stock.Percentage Held by Insiders18.50% of the stock of Vivos is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Vivos' insider trading history. Receive RDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos and its competitors with MarketBeat's FREE daily newsletter. Email Address RDGL Stock News HeadlinesVivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025April 23, 2025 | globenewswire.comVivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™April 15, 2025 | globenewswire.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 2, 2025 | Stansberry Research (Ad)Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion PlansFebruary 4, 2025 | finance.yahoo.comVivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 27, 2024 | markets.businessinsider.comVivos Inc.'s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics NationwideDecember 26, 2024 | globenewswire.comVivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical TrialDecember 23, 2024 | globenewswire.comVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comSee More Headlines RDGL Stock Analysis - Frequently Asked Questions How have RDGL shares performed this year? Vivos' stock was trading at $0.1149 at the start of the year. Since then, RDGL shares have increased by 21.8% and is now trading at $0.1399. View the best growth stocks for 2025 here. How do I buy shares of Vivos? Shares of RDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vivos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos investors own include MannKind (MNKD), Agenus (AGEN), APA (APA), Aphria (APHA), Bionano Genomics (BNGO), Churchill Capital Corp IV (CCIV) and Canopy Growth (CGC). Company Calendar Today5/01/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorFinance Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:RDGL CIK1449349 Webwww.radiogel.com Phone(509) 736-4000Fax509-736-4007Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,890,000.00 Net MarginsN/A Pretax Margin-12,345.83% Return on EquityN/A Return on Assets-197.34% Debt Debt-to-Equity RatioN/A Current Ratio25.48 Quick Ratio25.48 Sales & Book Value Annual Sales$20,000.00 Price / Sales3,154.18 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-6.96Miscellaneous Outstanding Shares453,512,000Free Float369,805,000Market Cap$63.08 million OptionableNot Optionable Beta0.88 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (OTCMKTS:RDGL) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.